An open label post marketing surveillance assessment to evaulate the effectiveness and safety of Rapamune [sirolimus] in patients after kidney transplantation receiving a Rapamune containing regime

Trial Profile

An open label post marketing surveillance assessment to evaulate the effectiveness and safety of Rapamune [sirolimus] in patients after kidney transplantation receiving a Rapamune containing regime

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 13 Mar 2008

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 13 Mar 2008 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 21 Dec 2007 Status changed from recruiting to suspended.
    • 31 May 2007 Status changed from in progress to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top